Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT04379596
- Locations
- š¬š§
Research Site, Sutton, United Kingdom
NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04371224
- Locations
- š°š·
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
š°š·Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04366713
- Locations
- šµš¹
Hospital CUF Descobertas, Lisboa, Portugal
Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT04357587
- Locations
- šŗšø
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 319
- Registration Number
- NCT04355858
- Locations
- šØš³
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 25
- Registration Number
- NCT04340401
- Locations
- šØš³
Beijing Cancer Hospital, Beijing, China
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-04-08
- Target Recruit Count
- 493
- Registration Number
- NCT04337658
- Locations
- šØš³
Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
šØš³Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 65
- Registration Number
- NCT04333706
- Locations
- šŗšø
Los Angeles General Medical Center, Los Angeles, California, United States
šŗšøUF Health, Gainesville, Florida, United States
šŗšøUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 200
- Registration Number
- NCT04310176
- Locations
- š®š¹
Istituto Tumori di Napoli - Fondazione G. Pascale, Napoli, Campania, Italy
NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 316
- Registration Number
- NCT04307147
- Locations
- šØš³
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.